Financial Data and Key Metrics Changes - Consolidated gross profit for Q1 2025 was $22 million, a 7.9% increase over Q1 2024, marking the highest gross profit in the past twelve quarters [21] - Adjusted EBITDA for Q1 2025 was $7.8 million, compared to $6.2 million for Q1 2024, reflecting a growth of 14.4% [21] - Adjusted EPS for Q1 2025 was $0.63, up from $0.53 in Q1 2024, indicating an 18.9% increase [21] Business Line Data and Key Metrics Changes - In the healthcare segment, gross profit for Q1 2025 was $12.2 million, compared to $11.1 million in Q1 2024, a growth of 10.2% [21] - Engineering gross profit for Q1 2025 was $6.2 million, up from $5.5 million in Q1 2024, representing a 12.4% increase, marking the best engineering gross profit quarter in history [21][22] - In IT, life sciences, and data solutions, gross profit for Q1 2025 was $3.6 million, down from $3.8 million in Q1 2024, a decline of 5.3% [24] Market Data and Key Metrics Changes - School revenue for Q1 2025 was $37.3 million, compared to $31.9 million in Q1 2024, reflecting a growth of 16.7% [22] - Non-school revenue for Q1 2025 was $6 million, slightly down from $6.3 million in Q1 2024, but would have been $5.5 million versus $5.1 million if excluding a large long-term care group [22] Company Strategy and Development Direction - The company is focused on cultivating the next generation of leadership and enhancing operational efficiency through strategic investments [4][12] - There is a strong emphasis on expanding the sales team to capitalize on growth opportunities in various sectors, particularly in healthcare and life sciences [5][7] - The company aims to maintain a clean balance sheet while continuing to repurchase shares, enhancing shareholder value [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating macroeconomic uncertainties, focusing on secular themes that can drive growth [30][31] - The outlook for the healthcare segment remains positive, with expectations for continued growth in the upcoming school year [5][6] - The aerospace and defense sectors are anticipated to see significant growth due to new contracts and increased demand for engineering services [16][19] Other Important Information - The company has reduced net debt by $12 million to $18.2 million in Q1 2025, compared to $30.2 million in Q4 2024 [26] - The company has maintained a 90% plus renewal rate while preserving margins and bottom line strength [9] Q&A Session Summary Question: Is political policy uncertainty affecting the business? - Management indicated that they have not encountered significant issues related to the macroeconomic environment and are focused on leveraging secular themes for growth [30][31] Question: Regarding healthcare gross margins, is the lower margin due to legacy business? - Management clarified that the lower gross margin is more of a quarterly fluctuation rather than a trend, with expectations for improvement in Q2 [32][33]

Company Overview - Bio-Techne Corporation is a global life sciences company that provides innovative tools and bioactive reagents for research and clinical diagnostics [2] - The company generated approximately $1.2 billion in net sales in fiscal 2024 and employs over 3,100 people worldwide [2] Upcoming Events - Kim Kelderman, President and CEO of Bio-Techne, will present at the BofA Securities 2025 Health Care Conference on May 13, 2025, at 10:40 a.m. PDT [1]

© 2025 Azenta, Inc. • All rights reserved 1 Conference Call Fiscal Second Quarter 2025 Financial Results May 7, 2025 1 Safe Harbor Statement "Safe Harbor" Statement under the U.S. Private Securities Litigation Reform Act of 1995; certain matters in this presentation, including forecasts of future demand and future Company performance, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to materially differ, either better or worse, from those projected. ...

Core Insights - The company reported a total revenue of $143 million for the quarter ended March 31, 2025, reflecting a 5% increase year-over-year, driven by growth in Sample Management Solutions and Multiomics [2][7] - The diluted EPS from continuing operations was $(0.40), compared to $(0.29) in the same quarter of the previous year, indicating a significant loss [2][24] - The company has a strong cash position with total cash, cash equivalents, and marketable securities amounting to $540 million as of March 31, 2025 [14] Financial Performance - Revenue from continuing operations was $143 million, down 3% from the previous quarter but up 5% year-over-year [2][7] - Organic revenue growth was 6% year-over-year, with Sample Management Solutions revenue at $80 million, up 8% year-over-year [2][7] - Adjusted EBITDA for continuing operations was $14 million, with an adjusted EBITDA margin of 10.0%, an improvement of 400 basis points year-over-year [2][7] Management Commentary - The CEO highlighted the company's strong performance amidst a challenging macroeconomic environment, emphasizing the resilience of the portfolio and the commitment of the teams [3] - The management expressed confidence in the company's positioning and disciplined operations while navigating uncertainties [3] Cash Flow and Guidance - Operating cash flow for the quarter was $14 million, with capital expenditures of $7 million, resulting in free cash flow of $7 million [14] - The company reiterated its revenue guidance for fiscal year 2025, expecting total organic revenue growth in the range of 3% to 5% compared to fiscal 2024 [14]

Company Overview - Qiagen NV is a Netherlands-based holding company that provides "Sample to Insight" solutions, transforming biological samples into molecular insights through integrated sample and assay technologies, bioinformatics, and automation systems [1] - The company specializes in isolating and preparing DNA, RNA, and proteins from various biological materials, and its assay technologies enable the analysis of these biomolecules [1] - Qiagen operates primarily in two end markets: Molecular Diagnostics and Life Sciences, generating approximately 90% of its sales from recurring consumables revenue [4] Investment Context - Fivespan Partners has established a position in Qiagen and is engaging with its management to explore potential improvements [3][7] - Qiagen has struggled to create shareholder value post-Covid, with 1-, 3-, and 5-year returns of 1%, -6%, and 1%, respectively, while trading at around 13 times EV/EBITDA compared to peers at approximately 15 times [5] - The company has a strong market position and brand reputation but has lost focus on its core business, leading to missed opportunities for growth [6] Strategic Opportunities - Management is encouraged to invest more in its core business, improve communication with the market, and optimize its balance sheet to enhance shareholder value [6] - Qiagen's operating margin is currently at 25%, with potential for expansion to over 30% through a more disciplined approach [6] - The company holds $1.15 billion in cash and short-term investments against $1.39 billion in debt, suggesting room for leveraging to fund growth initiatives and share buybacks [6] Market Dynamics - Qiagen's dual-listing and geographical revenue distribution show that 52% of its FY24 sales are from North America, 32% from Europe, the Middle East, and Africa, and 16% from Asia [4] - The company has previously engaged in discussions for potential transactions, including a failed offer from Thermo Fisher Scientific at 43 euros per share, indicating its attractiveness as an acquisition target [8] - Fivespan's investment philosophy includes evaluating strategic transactions, and while it does not prioritize sales, it remains open to advocating for shareholder value in the event of acquisition offers [8]

Core Viewpoint - Bio-Techne Corporation (TECH) is expected to report its third-quarter fiscal 2025 results on May 7, with positive earnings and revenue growth anticipated based on recent performance and market trends [1][2]. Group 1: Financial Performance Estimates - The Zacks Consensus Estimate for Bio-Techne's revenues is $315.2 million, reflecting a 3.9% increase from the previous year [2]. - The consensus estimate for EPS is projected at 51 cents, indicating a 6.3% year-over-year improvement [2]. - Recent estimates for EPS have decreased by 1.9% over the past 30 days [2]. Group 2: Segment Performance Insights - The Protein Sciences segment is expected to benefit from its protein analysis portfolio and GMP protein business, with revenues estimated at $224.7 million, up 4.7% from the prior year [3][5]. - The Diagnostics and Spatial Biology segment is anticipated to show solid growth, particularly in the spatial biology vertical, with revenues estimated at $92.5 million, a 5.7% increase from the previous year [6][9]. Group 3: Recent Developments and Innovations - Bio-Techne launched its Simple Western platform called Leo, which allows for high-throughput analysis of samples [4]. - The company expanded its geographic reach through new distribution agreements in Turkey and Azerbaijan, which may positively impact revenue [4]. - The Precision Diagnostic Tools business is experiencing growth, with a unique portfolio that continues to gain market share [7]. Group 4: Collaborations and Product Launches - Bio-Techne's Asuragen brand collaborated with Oxford Nanopore Technologies to launch a new genetic panel, which is expected to enhance business performance [9]. - The company also expanded its menu of RNAscope in situ hybridization probes to support spatial biology research and next-generation therapeutics [8].

ExlService Holdings Inc. First Quarter 2025 financial results April 29, 2025 Safe harbor Forward-looking statements This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. You should not place undue reliance on those statements because they are subject to numerous uncertainties and factors relating to EXL's operations and business environment, all of which are difficult to predict and many of which are beyond EXL's contr ...

Core Viewpoint - Rakovina Therapeutics Inc. has appointed Mr. Yevgeniy Meshcherekov and Dr. David Kideckel to its board of directors, enhancing its governance and financial expertise as it advances its AI-driven cancer therapies [1][6][7]. Group 1: Appointments and Governance - Mr. Yevgeniy Meshcherekov brings over 20 years of experience in financial management across various industries, including fintech and blockchain [2][3]. - Dr. David Kideckel has nearly 20 years of experience in the Life Sciences sector, having held senior roles in healthcare and biotechnology, including at Johnson & Johnson and Alexion Pharmaceuticals [5][6]. - The appointments are aimed at strengthening Rakovina's financial and capital markets infrastructure in preparation for upcoming drug development milestones [6][7]. Group 2: Leadership Changes - Michael Liggett has retired from the board, having significantly contributed to the company's strategic direction and growth in the healthcare sector [8][9]. - The transition in leadership is expected to drive fiscal discipline and operational scale as the company continues to develop its oncology programs [7]. Group 3: Company Overview - Rakovina Therapeutics focuses on innovative cancer treatments using AI technologies, specifically targeting DNA-damage response through its proprietary platforms [9][10]. - The company aims to advance its pipeline of DNA-damage response inhibitors into human clinical trials in collaboration with pharmaceutical partners [10].

Financial Data and Key Metrics Changes - Company reported a 13% year-over-year sales growth to $3.7 billion in Q1 2025, with EPS growing more than three times the rate of sales to $0.54 [5][32] - Operating margin expanded by 250 basis points year-over-year to 18% [5][32] - For Q2 2025, the company expects sales to be approximately $3.85 billion and EPS guidance of $0.55 to $0.59, indicating a year-over-year EPS growth of about 21% [6][32] Business Line Data and Key Metrics Changes - Optical communications sales were $1.4 billion, up 46% year-over-year, with net income increasing by 101% [35] - Enterprise sales reached $705 million, up 106% year-over-year, driven by demand for new Gen AI products [35] - Display sales were $905 million, up 4% year-over-year, with a net income margin of 26.9% [37] - Specialty materials sales increased by 10% year-over-year to $501 million, with net income growing 68% [39] - Automotive sales were $440 million, down 10% year-over-year, primarily due to softness in European markets [42] Market Data and Key Metrics Changes - The company noted strong demand for US-made innovations, particularly in optical communications and solar sectors [14][26] - In the solar market, the company expects to grow from a $1 billion business in 2024 to a $2.5 billion business by 2028, driven by increased energy demand and favorable government policies [26][28] Company Strategy and Development Direction - The company is focused on its SpringBoard plan, aiming to add more than $4 billion in annualized sales and achieve a 20% operating margin by the end of 2026 [9][51] - The strategy includes leveraging US manufacturing capabilities to mitigate tariff impacts and capitalize on domestic demand [8][14] - The company is also emphasizing innovation in Gen AI and solar technologies as key growth drivers [22][51] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in delivering the SpringBoard plan even in a potential macroeconomic downturn, citing a risk-adjusted approach to planning [9][21] - The company is seeing early signs of stronger demand for US-made products, which is expected to positively impact financial performance [14][26] - Management reiterated that the direct impact of current tariffs is minimal, with a projected impact of $10 million to $15 million for Q2 2025 [13][34] Other Important Information - The company plans to invest approximately $1.3 billion in capital expenditures and expects to generate significant free cash flow in 2025 [45][46] - The company has a strong balance sheet with a long average debt maturity of about 23 years [47] Q&A Session Summary Question: Pricing power in uncertain markets - Management highlighted their ability to pass on increased costs to customers, particularly in solar and optical segments, due to strong demand and unique product offerings [54][56] Question: Temporary capacity ramp costs - Management clarified that the costs associated with ramping up production are primarily operational expenses, not capital expenditures, and are expected to normalize as production scales [59][60] Question: Visibility in Gen AI orders - Management confirmed strong demand from major hyperscale customers, reinforcing growth expectations despite potential market fluctuations [64] Question: Supply constraints in optical segment - Management acknowledged supply constraints and indicated that pricing power could strengthen further with the introduction of next-generation products [69][71] Question: Customer conversations regarding tariffs and recession - Management noted increasing demand for US-based manufacturing and emphasized the importance of long-term commitments from customers amid tariff uncertainties [78][79] Question: End market demand in display segment - Management expects flat unit demand for displays but anticipates growth in the glass market driven by increasing screen sizes [87][88]

NEW YORK, April 29, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Maravai LifeSciences Holdings, Inc. ("Maravai LifeSciences" or the "Company") (NASDAQ: MRVI) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Maravai LifeSciences investors who were adversely affected by alleged securities fraud between August 7, 2024 and February 24, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zl ...